Celldex to stop skin disease study after trial setback

July 21st, 2026 | 20:44 PM BUSINESS Healthcare & Pharmaceuticals 1

Facebook Twitter Google+ LinkedIn Pinterest
By Reuters

Celldex Therapeutics (CLDX.O) said on Tuesday it would discontinue the ​development of its experimental drug for a skin disease ‌after it failed to meet the main goal and key secondary goals in a mid-stage study, sending its shares down over 7% in ​extended trading.

Here are some details:

Related Posts

© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT